Invasive ductal carcinoma (IDC) is the most common histological subtype of breast cancer, accounting for 70-80% of all breast malignancies. It originates from ductal epithelial cells and has invaded beyond the basement membrane into the surrounding breast stroma (invasive, not in-situ). Typically occurs in women aged 50-70; rare but possible in men. On ultrasonography, appears as a spiculated, non-parallel oriented (taller-than-wide), heterogeneously hypoechoic solid mass usually demonstrating posterior acoustic shadowing — classified as BI-RADS 5 (highly suggestive of malignancy). On mammography, spiculated high-density mass, associated pleomorphic microcalcifications, architectural distortion, and skin retraction/thickening may be observed. On MRI, heterogeneous enhancement, irregular margins, and Type III (washout) kinetic curve are the strongest indicators of malignancy. Marked diffusion restriction and low ADC values (<1.0 × 10⁻³ mm²/s) on DWI reflect high cellularity. Treatment requires a multidisciplinary approach: surgery (lumpectomy/mastectomy), chemotherapy, radiotherapy, and hormonal/targeted therapy are planned according to molecular subtype.
Age Range
40-80
Peak Age
60
Gender
Female predominant
Prevalence
Common
IDC is a cancer that begins with malignant transformation of breast ductal epithelial cells and invades through the basement membrane into surrounding stroma. Pathogenesis is multistep: normal ductal epithelium → atypical ductal hyperplasia → ductal carcinoma in-situ (DCIS) → invasive ductal carcinoma. Genetic and epigenetic changes accumulate during this process — TP53 mutation, PIK3CA mutation, HER2 amplification, and hormone receptor expression changes (ER/PR) are key mechanisms. Tumor cells stimulate desmoplastic stromal reaction (fibrous tissue proliferation); this dense fibrous stroma forms the basis of spiculated margins on mammography and posterior acoustic shadowing on US — resulting from collagen fibrils absorbing sound waves and increasing X-ray attenuation. Neoangiogenesis (VEGF-mediated) provides blood supply to the tumor and forms the basis of enhancement on MRI; arteriovenous shunts cause rapid contrast accumulation and rapid washout → Type III kinetic curve. High cellularity restricts intracellular water molecule movement → diffusion restriction on DWI and low ADC. Pleomorphic microcalcifications develop as dystrophic calcification within and around tumor cells (in necrotic areas) or secretory calcification (abnormal ductal secretion).
The presence of a spiculated high-density mass together with fine pleomorphic or fine linear microcalcifications on mammography is the finding combination with the highest positive predictive value (95%+) for breast cancer (IDC). BI-RADS 5 classification is made in the presence of this finding and urgent biopsy is indicated.
Spiculated, non-parallel oriented (taller-than-wide), heterogeneously hypoechoic solid mass. Posterior acoustic shadowing is prominent — sound wave attenuation is increased due to dense desmoplastic stroma. Margins are irregular with extensions (spicules) showing invasion into surrounding tissue. Internal echoes are heterogeneous — reflecting differences in necrosis, fibrosis, and cellularity. Non-parallel orientation (taller-than-wide) reflects the infiltrative growth pattern indicating the tumor grows vertically across tissue planes. Classified as BI-RADS 5.
Report Sentence
A spiculated, non-parallel oriented, heterogeneously hypoechoic solid mass is seen in the breast with prominent posterior acoustic shadowing; findings are highly consistent with invasive breast carcinoma and assessed as BI-RADS 5.
Spiculated, high-density irregular mass on mammography — the most classic IDC appearance. Associated fine pleomorphic or fine linear microcalcifications have a high positive predictive value for malignancy (90%+). Architectural distortion may be seen even without a mass and can be a sign of occult carcinoma. Skin retraction, skin thickening, and nipple retraction suggest locally advanced disease. Newly developing focal asymmetry and density increase are also among mammographic presentations of IDC.
Report Sentence
Mammography demonstrates a spiculated, high-density irregular mass with associated segmentally distributed fine pleomorphic microcalcifications; architectural distortion and skin retraction are present; findings are highly consistent with invasive breast carcinoma and assessed as BI-RADS 5.
Irregularly marginated mass with heterogeneous enhancement on contrast-enhanced breast MRI. Kinetic curve analysis demonstrates Type III (washout) pattern — early rapid enhancement followed by significant washout. This pattern has the highest positive predictive value for malignancy (87%). Rim enhancement (peripheral enhancement + central necrosis) may be seen in aggressive tumors. Non-mass enhancement in surrounding parenchyma may accompany — suggests extensive DCIS component. Axillary lymphadenopathy should be evaluated for staging.
Report Sentence
Contrast-enhanced breast MRI reveals an irregularly marginated mass with heterogeneous enhancement; kinetic curve demonstrates Type III (washout) pattern; findings are consistent with invasive breast carcinoma; axillary region should be evaluated for lymphadenopathy.
On diffusion-weighted imaging (DWI), the tumor shows markedly high signal (diffusion restriction) and is hypointense on the ADC map — ADC values are usually <1.0 × 10⁻³ mm²/s. This reflects the high cellularity of the tumor. DWI provides additional diagnostic information alongside enhancement in breast MRI; malignancy probability is very high in lesions with ADC values <0.8 × 10⁻³ mm²/s. Triple-negative and high-grade tumors generally demonstrate the lowest ADC values.
Report Sentence
The mass demonstrates marked diffusion restriction on diffusion-weighted imaging and is hypointense on the ADC map; ADC value is below the malignancy threshold; this finding is consistent with high cellularity and supports the diagnosis of invasive carcinoma.
Architectural distortion is disruption of the normal breast parenchymal pattern in the form of radial lines and can be a mammographic finding of IDC even without a mass. A radiolucent or radiopaque focus at the center may or may not be present. Digital breast tomosynthesis (DBT/3D mammography) significantly increases detection sensitivity for architectural distortion — distortions that may be masked by superposition on 2D mammography become clearly visible on 3D slices.
Report Sentence
Architectural distortion is observed on mammography; although no definite mass is identified, radial lines and parenchymal distortion suggest the possibility of occult carcinoma; supplemental US and/or breast MRI is recommended.
Criteria
Hormone receptor positive (ER+/PR+), HER2 negative, low Ki-67 (<14%). Comprises ~40-50% of all IDCs. Molecular subtype with the best prognosis.
Distinct Features
Spiculated mass on mammography, usually slow-growing; less aggressive enhancement pattern on MRI; good response to endocrine therapy; 5-year survival >90%.
Criteria
HER2 amplification/overexpression present, hormone receptors negative. Comprises ~15-20% of all IDCs.
Distinct Features
Aggressive biology; rapidly growing mass on mammography; prominent enhancement on MRI; dramatic response to trastuzumab (Herceptin) targeted therapy; high pathological complete response rate with neoadjuvant chemotherapy.
Criteria
Estrogen receptor, progesterone receptor, and HER2 negative. Comprises ~15% of all IDCs. Subtype with the worst prognosis; strong association with BRCA1 mutation.
Distinct Features
May present as round/oval circumscribed mass on mammography (fibroadenoma mimic!); rim enhancement and T2 hyperintensity (necrosis) on MRI; very low ADC values; rapid growth; immunotherapy (pembrolizumab) is a new treatment option.
Distinguishing Feature
Invasive lobular carcinoma is frequently occult on mammography; may not form a distinct mass due to single-file infiltration pattern. Non-mass enhancement is more common on MRI. IDC shows a distinct mass with spiculated margins.
Distinguishing Feature
Fibroadenoma is a parallel-oriented, circumscribed, homogeneously hypoechoic mass with posterior enhancement. IDC is non-parallel, spiculated, heterogeneous, with posterior shadowing. On kinetic curve, fibroadenoma shows Type I, IDC shows Type III.
Distinguishing Feature
Radial scar can mimic IDC with architectural distortion and spiculated appearance on mammography; however the center of radial scar is radiolucent (fat density) and its size changes with different mammographic positions. The center of IDC is usually high density and size is fixed.
Distinguishing Feature
Fat necrosis in patients with trauma/surgery history can mimic IDC with spiculated mass, architectural distortion, or calcification. Fat-containing radiolucent center (oil cyst) and coarse calcifications on mammography support fat necrosis; fat content is not expected in IDC.
Distinguishing Feature
DCIS usually presents as segmental/linear distributed microcalcifications without a mass on mammography; basement membrane is not breached (in-situ). IDC forms a distinct mass with invasive component. On MRI, DCIS shows non-mass enhancement, IDC shows mass enhancement.
Urgency
emergentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralUrgent core biopsy (14 gauge, US or stereotactic-guided) is indicated for IDC diagnosis. After biopsy, multidisciplinary tumor board (surgical oncology, medical oncology, radiation oncology, radiology, pathology) determines the treatment plan. Staging studies: contralateral breast MRI (extent and multifocality), axillary US ± FNA (lymph node evaluation), metastasis screening (CT chest/abdomen, bone scintigraphy — stage II and above). Surgery: breast-conserving surgery (lumpectomy + sentinel lymph node biopsy) or mastectomy + axillary dissection. Systemic therapy: chemotherapy (neoadjuvant or adjuvant), hormone therapy (ER+ cases), anti-HER2 therapy (HER2+ cases), immunotherapy (triple-negative). Radiotherapy: standard after breast-conserving surgery; in selected cases after mastectomy. Prognosis depends on stage, grade, molecular subtype, lymph node status, and treatment response — 5-year survival >95% in early-stage IDC (T1N0).
IDC is the most common type of breast cancer. Biopsy is mandatory for BI-RADS 5 (highly suggestive of malignancy) lesions. Treatment includes surgery (lumpectomy/mastectomy), chemotherapy, radiotherapy, and hormonal therapy. TNM staging and molecular subtype (ER/PR/HER2) determine the treatment plan.